Clinical value of non-invasive advanced glycation end product measurement in screening for diabetes mellitus and impaired glucose tolerance / 中华健康管理学杂志

ABSTRACT

Objective To evaluate the clinical value of non-invasive skin autofluorescence measurement of advanced glycation end products (AGE) to screen for both diabetes mellitus and impaired glucose tolerance (IGT). Methods A total of 389 individuals who underwent physical examination at Renmin Hospital of Wuhan University from December 2016 to August 2017, and were willing to participate were enrolled in our study. 293 people meeting the criteria were included finally. AGE value in the skin tissue was measured non-invasively via autofluorescence with the DM Scanner. Two-hour oral glucose tolerance testing, and measurements of fasting blood glucose and glycosylated hemoglobin were also performed for each patient. Results Among 293 subjects, 209 had normal glucose metabolism, 50 had IGT, and 34 had diabetes mellitus. The measured Advanced glycation end product values in these groups were (69.44 ± 7.28) AU, (79.67 ± 5.65) AU, and (81.17 ± 9.28) AU, respectively. The differences between groups were statistically significant (P<0.05). Pearson correlation analysis showed a significant positive correlation between autofluorescence measurements and fasting blood glucose, glycosylated hemoglobin and glucose level 2 hours after oral glucose loading (r=0.472, 0.433, and 0.546, respectively;P<0.001). The sensitivity of DM Scan screening for IGT was 84.00％, with a specificity of 84.87％. For diabetes mellitus, the sensitivity was 79.41％, and the specificity 84.87％. Conclusion DM Scan has high sensitivity in screening for diabetes mellitus and IGT. It has important clinical value in the early diagnosis of IGT.